Current News

Contact | Print version | Send article | RSS feed

Oncomethylome Sciences achieves key milestone in Schering-Plough collaboration

25 Aug 2006 - OncoMethylome Sciences announced that it achieved a key milestone in its collaboration with Schering-Plough. Schering-Plough has approved OncoMethylome Sciences' sub contractor, BRT Laboratories (Maryland, USA) as a clinical trial testing facility. The laboratory can now start to provide testing services for clinical trials that are an important component of the collaboration. This event triggers a milestone payment for OncoMethylome Sciences, who will also qualify to receive ongoing sample processing fees.
 
Starting immediately, the laboratory will be evaluating the methylation status of the MGMT gene in DNA extracted from brain tumor cells using OncoMethylome Sciences' patent-protected assay. Making this testing service available is a key milestone in OncoMethylome Sciences' collaboration with Schering-Plough. The tumor samples will originate from the multi-center brain cancer clinical trial conducted by the U.S.-based Radiation Therapy Oncology Group (RTOG), the European Organization for Research and Treatment of Cancer (EORTC), and supported by Schering-Plough.